Indivior Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Indivior Pharmaceuticals Inc.
- Former names
- Indivior PLC
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- North Chesterfield
- Headquarters state / province
- Virginia
- Headquarters country
- United Kingdom
- Fiscal year end
- December
- Ticker symbol
- INDV
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001625297
- EIN
- 41-2520873
Board of directors
-
Barbara Ryan · DirectorSince 2026
-
Daniel A. Ninivaggi · DirectorSince 2026
-
David E. Wheadon · DirectorSince 2026
-
Joseph Ciaffoni · Director · Chief Executive OfficerSince 2026
-
Juliet Thompson · DirectorSince 2026
-
Keith Humphreys · DirectorSince 2026
-
Mark Stejbach · DirectorSince 2026
-
Stuart A. Kingsley · DirectorSince 2026
Chief executives
Joseph Ciaffoni
· Chief Executive Officer
Since January 2026
Director election results
Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.2%
-
98.4%
-
98.6%
-
99.2%
-
99.9%
-
99.9%
-
99.9%
Board connections
4 of this board's directors also sit on 7 other boards.
- via Barbara Ryan
- via Joseph Ciaffoni
- via Daniel A. Ninivaggi
- via Barbara Ryan
- via Barbara Ryan
- via David E. Wheadon
- via David E. Wheadon
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $311,556
- 10 purchases by 7 insiders
- Sold, last 12 months
- $2,829,211
- 3 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 27, 2026 | Anderson Woodrow D Officer (Chief Accounting Officer) | Open-market purchase | +1,500 | $35.69 | $53,535 |
| Aug 5, 2026 | Anderson Woodrow D Officer (Chief Accounting Officer) | Open-market purchase | +1,500 | $36.28 | $54,420 |
| Jul 10, 2026 | Heidbreder Christian Officer (Chief Scientific Officer) | Open-market sale | −18,586 | $41.14 | $764,628 |
| Jun 22, 2026 | Joseph Ciaffoni Director, Officer (Chief Executive Officer) | Option exercise | +1,266,903 | — | — |
| Jun 22, 2026 | Joseph Ciaffoni Director, Officer (Chief Executive Officer) | Shares withheld for tax | −612,549 | $38.32 | $23,472,878 |
| Jun 11, 2026 | Heidbreder Christian Officer (Chief Scientific Officer) | Open-market sale | −18,586 | $38.06 | $707,383 |
| Jun 8, 2026 | Preblick Ryan Officer (Chief Financial Officer) | Open-market sale | −36,000 | $37.70 | $1,357,200 |
| May 13, 2026 | Keith Humphreys Director | Grant or award | +6,518 | — | — |
| May 13, 2026 | Stuart A. Kingsley Director | Grant or award | +6,518 | — | — |
| May 13, 2026 | Daniel A. Ninivaggi Director | Grant or award | +6,518 | — | — |
| May 13, 2026 | Barbara Ryan Director | Grant or award | +6,518 | — | — |
| May 13, 2026 | Mark Stejbach Director | Grant or award | +6,518 | — | — |
| May 13, 2026 | David E. Wheadon Director | Grant or award | +10,430 | — | — |
| May 13, 2026 | Juliet Thompson Director | Grant or award | +6,518 | — | — |
| May 12, 2026 | Juliet Thompson Director | Shares withheld for tax | −1,117 | $38.28 | $42,759 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.